此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

首次在 HLA-A*02:01 表达 MAGE-A4 的实体瘤参与者中进行 CDR404 人体研究

2026年9月21日 更新者:CDR-Life AG

第一阶段首次人体研究,旨在评估 CDR404 在表达 MAGE-A4 的实体瘤 HLA-A*02:01 参与者中的安全性、耐受性和抗肿瘤活性

CDR404 is a highly potent and specific T-cell engaging bispecific and bivalent antibody designed for the treatment of cancers positive for the tumor-associated antigen melanoma-associated antigen 4 (MAGE-A4). This is a first-in-human study designed to evaluate the safety, tolerability, and preliminary anti-tumor activity of CDR404 in adult patients who have the appropriate germline human leukocyte antigen HLA-A*02:01 tissue marker and whose cancer is positive for MAGE-A4.

研究概览

地位

招聘中

干预/治疗

详细说明

The CDR404-001 Phase 1 study will enrol patients with locally advanced, unresectable or metastatic tumors expressing MAGE-A4, which include advanced solid tumors, and will be conducted in multiple phases:

  1. To identify the maximum tolerated dose (MTD) and pharmacologically effective dose range (PEDR) for CDR404
  2. To assess preliminary evidence of anti-tumor activity of CDR404
  3. To characterise the pharmacokinetics of CDR404
  4. To characterise the immunogenicity of CDR404
  5. To assess translational biomarkers

研究类型

介入性

注册 (估计的)

42

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Milan、意大利、20141
        • 招聘中
        • Isituto Europeo di Oncologia (IEO)
        • 接触:
        • 首席研究员:
          • Guiseppe Curigliano, MD
      • Milan、意大利、20089
      • Antwerp、比利时、2650
        • 招聘中
        • Universitair Ziekenhuis Antwerpen
        • 首席研究员:
          • Hans Prenen, MD
        • 接触:
      • Brussels、比利时、1070
        • 招聘中
        • Institut Jules Bordet
        • 首席研究员:
          • Nuria Kotecki, MD
        • 接触:
      • Brussels、比利时、1200
        • 招聘中
        • Cliniques Universitaires Saint-Luc, UCL Ouvain
        • 接触:
        • 首席研究员:
          • Jean-Pascal Machiels, MD
      • Ghent、比利时、9000
        • 招聘中
        • Universitair Ziekenhuis Gent
        • 首席研究员:
          • Sylvie Rottey, MD
        • 接触:
    • Florida
      • Miami、Florida、美国、33136
        • 撤销
        • University of Miami
    • Michigan
      • Ann Arbor、Michigan、美国、48109
        • 撤销
        • University of Michigan
    • Oregon
      • Portland、Oregon、美国、97213
        • 招聘中
        • Providence Cancer Institute
        • 首席研究员:
          • Rom Leidner, MD
        • 接触:
        • 接触:
          • 电话号码:+1-503-215-5763
    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、19106
        • 招聘中
        • Pennsylvania Hospital
        • 首席研究员:
          • Mark Diamond, MD
        • 接触:
      • Glasgow、英国
        • 招聘中
        • The Beatson West of Scotland Cancer Center
        • 首席研究员:
          • Jeff Evans
        • 接触:
      • London、英国
        • 尚未招聘
        • Guys and St Thomas' NHS Foundation Trust
        • 首席研究员:
          • Rebecca Kristeleit
        • 接触:
    • London
      • Sutton、London、英国、SM2 5PT
        • 招聘中
        • Royal Marsden Hospital
        • 接触:
        • 首席研究员:
          • Alec MD Paschalis
      • Barcelona、西班牙、08035
        • 招聘中
        • Hospital Universitari Vall d'Hebron
        • 接触:
        • 首席研究员:
          • Alberto Hernando Calvo, MD
      • Barcelona、西班牙、08908
        • 招聘中
        • Institut Catala d'Oncologia, L'Hospitalet de Llobregat (ICO)
        • 接触:
        • 首席研究员:
          • Ramon Salazar MD Martin, MD
      • Madrid、西班牙、28041
        • 招聘中
        • Hospital 12 de Octubre
        • 接触:
        • 接触:
          • Sandra de la Llave, Marta Gutierrez, Elisa Lorente, Lidia Silvo, Veronica Silva
        • 首席研究员:
          • Guillermo de Velasco, MD
      • Madrid、西班牙、28050
      • Valencia、西班牙、46026
        • 招聘中
        • Hospital Universitari i Politecnic La Fe
        • 接触:
        • 接触:
        • 首席研究员:
          • Guillermo Suay Montagud, MD
      • Valencia、西班牙、46026
        • 招聘中
        • Instituto de Investigacion Sanitaria (INCLIVA)
        • 接触:
        • 接触:
          • Inma Blasco
        • 首席研究员:
          • Desamparados Roda Perez, MD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Provision of written informed consent
  2. HLA-A*02:01 positive
  3. MAGE-A4 positive tumor
  4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) [ECOG PS] 0 or 1
  5. Selected advanced solid tumors
  6. Relapsed from, refractory to, or intolerant of standard therapy
  7. Measurable disease per RECIST v1.1
  8. Adequate organ function
  9. If applicable, must agree to use highly effective contraception

Exclusion Criteria:

  1. Symptomatic or untreated central nervous system metastasis
  2. Inadequate washout from prior anticancer therapy
  3. Significant ongoing toxicity from prior anticancer treatment
  4. Recent surgery
  5. Clinically significant cardiac disease
  6. Active infection requiring systemic antibiotic treatment
  7. Human immunodeficiency virus (HIV) at risk of acquired immunodeficiency syndrome (AIDS)-related outcomes
  8. Active hepatitis B virus (HBV) or hepatitis C virus (HBC)
  9. Ongoing treatment with systemic steroids or other immunosuppressive therapies
  10. Significant secondary malignancy
  11. History of chronic or recurrent active autoimmune disease requiring treatment
  12. Uncontrolled intercurrent illness
  13. Pregnancy or lactation.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:顺序分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:CDR404

Dose escalation

IV infusions

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Presence of dose limiting toxicities (DLTs)
大体时间:From first dose to DLT period (21 days)

per Protocol

From first dose to DLT period (21 days)
Incidence and severity of (serious) adverse events ([S]AEs)
大体时间:From first dose to 90 days after the last dose

AEs, SAEs

From first dose to 90 days after the last dose
Anti-tumor response: Overall Response Rate (ORR)
大体时间:From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months

per RECIST 1.1

From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months

次要结果测量

结果测量
措施说明
大体时间
Disease control rate (DCR)
大体时间:From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months

per RECIST 1.1

From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
Duration of response (DOR)
大体时间:From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months

per RECIST 1.1

From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
Progression-free Survival (PFS)
大体时间:From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months

per RECIST 1.1

From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
Overall Survival (OS)
大体时间:From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months

per RECIST 1.1

From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months
Maximum serum concentration of CDR404 (Cmax)
大体时间:At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)

following single and multiple dose administration

At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
Time to maximum serum concentration of CDR404 (Tmax)
大体时间:At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)

following single and multiple dose administration

At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
Trough serum concentration of CDR404 (Ctrough)
大体时间:At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)

following single and multiple dose administration

At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
Half-life of CDR404 (t1/2)
大体时间:At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)

following single and multiple dose administration

At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
Area under the CDR404 serum concentration over time curve (AUC0-T)
大体时间:At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)

to the end of the dosing interval following single and multiple dose administration

At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
Volume of CDR404 distribution (Vd)
大体时间:At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)

following single and multiple dose administration

At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
Average serum concentration of CDR404 (Cavg)
大体时间:At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)

following single and multiple dose administration

At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
Serum drug levels of CDR404 at steady state (CL)
大体时间:At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)

following single and multiple dose administration

At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
Accumulation ratio of CDR404 (Rac)
大体时间:At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)

following single and multiple dose administration

At the end of Cycle 1 and Cycle 2 (each cycle is 21 days)
Immunogenicity
大体时间:From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months

Incidence of detectable anti-CDR404 antibodies (ADAs)

From first dose until date of first documented progression or date of death from any cause, whichever comes first, assessed up to 100 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年5月24日

初级完成 (估计的)

2026年12月30日

研究完成 (估计的)

2027年12月31日

研究注册日期

首次提交

2024年4月25日

首先提交符合 QC 标准的

2024年5月2日

首次发布 (实际的)

2024年5月7日

研究记录更新

最后更新发布 (实际的)

2026年9月24日

上次提交的符合 QC 标准的更新

2026年9月21日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • CDR404-001

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅